Cover Image

Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma

Objective For more than two decades, high-dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B-cell non-Hodgkin's lymphoma (B-NHL). However, the ideal timing and the collective patient benefits are still being debat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kriegsmann, Katharina (Author) , Rieger, Michael (Author) , Schwarzbich, Mark-Alexander (Author) , Sitter, Sören (Author) , Kriegsmann, Mark (Author) , Bruckner, Thomas (Author) , Hensel, Manfred (Author) , Ho, Anthony Dick (Author) , Witzens-Harig, Mathias (Author) , Wuchter, Patrick (Author)
Format: Article (Journal)
Language:English
Published: 25 March 2018
In: European journal of haematology
Year: 2018, Volume: 101, Issue: 1, Pages: 12-20
ISSN:1600-0609
DOI:10.1111/ejh.13064
Online Access:Verlag, Volltext: https://doi.org/10.1111/ejh.13064
Verlag: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13064
Get full text
Author Notes:Katharina Kriegsmann, Michael Rieger, Mark-Alexander Schwarzbich, Sören Sitter, Mark Kriegsmann, Thomas Bruckner, Manfred Hensel, Anthony Dick Ho, Mathias Witzens‐Harig, Patrick Wuchter
Description
Summary:Objective For more than two decades, high-dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B-cell non-Hodgkin's lymphoma (B-NHL). However, the ideal timing and the collective patient benefits are still being debated. Method We retrospectively analyzed the data of 163 patients with B-NHL who received an HDT protocol followed by ABSCT between 2001 and 2007. Patients were analyzed according to the time point of HDT/ABSCT to compare upfront (directly after induction, n = 72, 44%) versus secondary transplantation (at first relapse, n = 91, 56%). Results The overall response rate was 100% and 94% after upfront and secondary HDT/ABSCT, respectively. No significant differences were found for hematopoietic recovery and toxicity profile. The progression-free survival (PFS) and overall survival (OS) probability were found to be significantly higher in the upfront HDT/ABSCT treatment group (P = .018 and P = .004). In multivariate analysis, upfront HDT/ABSCT and low IPI risk score had a significant beneficial effect on OS (P = .031 and P = .019). Conclusion HDT and ABSCT directly after induction chemotherapy were confirmed to be feasible with high PFS and OS rates. In addition, for patients with relapse after first-line therapy and consecutively poor prognosis, HDT/ABSCT also offers an effective treatment strategy.
Item Description:Gesehen am 29.10.2019
Physical Description:Online Resource
ISSN:1600-0609
DOI:10.1111/ejh.13064

Similar Items